| Project/Area Number |
18K17181
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | ビスホスホネート / 顎骨壊死 / デノスマブ / 間葉系幹細胞 / 細胞シート / 再生医療等製品 / 骨粗鬆症 / 骨転移 / 薬剤性顎骨壊死 / 抗RANKL抗体製剤 / ビスフォスフォネート / 骨髄炎 / ビーグル犬 / 次世代シーケンサー |
|---|
| Outline of Final Research Achievements |
We investigated the use of mesenchymal stem cell sheets as a novel treatment for bisphosphonate-related osteonecrosis of the jaw (BRONJ), for which there is still no clear treatment. We had previously confirmed the efficacy in experiments using rats. As a translational research aimed at the clinical study, we conducted an experiment using beagle dogs and showed the same efficacy as the rat experiment. In addition, since the pathogenesis of BRONJ is not fully understood, gingival-derived mesenchymal stem cells collected from patients were comprehensively analyzed for genes by next-generation sequencing. We will report the results in the future.
|
| Academic Significance and Societal Importance of the Research Achievements |
BRONJは骨粗鬆症やがん患者にとって重大な懸念となっているが、明確な治療法が確立しているとは言えず、対応に苦慮している。治療戦略として、軽症例のうちに治癒を得ることが重要であるが、現在の治療のコンセンサスでは根本的な治癒が得られる治療法は確立しているとは言えない。今回の研究で、間葉系幹細胞シートによるBRONJの治療は画期的な新規治療法となり得ることを示した。
|
